Matthew Zirwas

2 weeks ago | dermatologytimes.com | Matthew Zirwas |Kaitlyn Bader

“If tofacitinib as a generic is easily accessible as something we can just write and people get it without a prior authorization, it's hard to describe how much that could revolutionize dermatology. It might actually be the end of prednisone,” said Matthew Zirwas, MD, in an interview with Dermatology Times.

2 weeks ago | dermatologytimes.com | Matthew Zirwas |Kaitlyn Bader

“Nemolizumab is a drug that we really should be thinking about in our patients who are particularly itchy and are willing to wait longer for the rash to get better, or willing to maybe not have the rash ever get quite as good as it could if we blocked IL-13 instead. But we don’t have any answer. We won’t have an answer unless we get a head-to-head trial,” said Matthew Zirwas, MD, in an interview with Dermatology Times.

Mar 18, 2025 | pharmacytimes.com | Aislinn Antrim |Matthew Zirwas

CommentaryVideoMarch 18, 2025Author(s):,Matthew Zirwas, MD, highlights the discrepancy between perceived and actual usage, citing studies that reveal patients often overestimate their compliance. In an interview with Pharmacy Times, Matthew Zirwas, MD, discusses the challenges of monitoring medication adherence, particularly with topical treatments such as ruxolitinib (Opzelura; Incyte).

Mar 14, 2025 | pharmacytimes.com | Aislinn Antrim |Matthew Zirwas

CommentaryArticleMarch 14, 2025Author(s):,Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs. In an interview with Pharmacy Times, Matthew Zirwas, MD, discusses the challenges and benefits of using ruxolitinib (Opzelura; Incyte) for atopic dermatitis and vitiligo.

Mar 11, 2025 | pharmacytimes.com | Aislinn Antrim |Matthew Zirwas

CommentaryVideoMarch 11, 2025Author(s):,Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo. In this interview with Pharmacy Times, Matthew Zirwas, MD, discusses common misconceptions and adherence challenges surrounding topical ruxolitinib (Opzelura; Incyte Dermatology) in vitiligo and atopic dermatitis.